120 related articles for article (PubMed ID: 34713867)
21. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
22. Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.
Sasamoto N; Vitonis AF; Fichorova RN; Yamamoto HS; Terry KL; Cramer DW
Cancer Causes Control; 2021 Mar; 32(3):299-309. PubMed ID: 33462738
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer.
Baskić D; Ristić P; Matić S; Banković D; Popović S; Arsenijević N
Biomarkers; 2007; 12(6):657-67. PubMed ID: 17852076
[TBL] [Abstract][Full Text] [Related]
24. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
25. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
Yonemori K; Katsumata N; Noda A; Uno H; Yunokawa M; Nakano E; Kouno T; Shimizu C; Ando M; Tamura K; Takeuchi M; Fujiwara Y
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1199-206. PubMed ID: 18528707
[TBL] [Abstract][Full Text] [Related]
26. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
Sandri MT; Salvatici M; Botteri E; Passerini R; Zorzino L; Rotmensz N; Luini A; Mauro C; Bagnardi V; Cassatella MC; Bottari F; Casadio C; Colleoni M
Breast Cancer Res Treat; 2012 Feb; 132(1):317-26. PubMed ID: 22065291
[TBL] [Abstract][Full Text] [Related]
28. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
30. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
34. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
36. Tumour markers in rheumatoid arthritis-associated interstitial lung disease.
Wang T; Zheng XJ; Ji YL; Liang ZA; Liang BM
Clin Exp Rheumatol; 2016; 34(4):587-91. PubMed ID: 27213221
[TBL] [Abstract][Full Text] [Related]
37. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
38. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study.
He J; Wang X; Xiao R; Zuo W; Zhang W; Yao H
Medicine (Baltimore); 2021 Mar; 100(9):e24724. PubMed ID: 33655937
[TBL] [Abstract][Full Text] [Related]
40. Correlation between cancer antigen 15.3 value and qualitative and semiquantitative parameters of positron emission tomography/computed tomography in breast cancer patients.
Cervino AR; Saibene T; Michieletto S; Ghiotto C; Bozza F; Saladini G; Evangelista L
Curr Radiopharm; 2014; 7(1):20-8. PubMed ID: 24836946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]